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Induced neuronsPantothenate kinase-associated neurodegeneration is an early onset autosomal recessive movement disorder
caused by mutation of the pantothenate kinase-2 gene, which encodes a mitochondrial enzyme involved in coen-
zymeAsynthesis. The disorder is characterisedbyhigh iron levels in thebrain, although thepathologicalmechanism
leading to this accumulation is unknown. To address this question,we tested primary skinﬁbroblasts from three pa-
tients and three healthy subjects, as well as neurons induced by direct ﬁbroblast reprogramming, for oxidative sta-
tus, mitochondrial functionality and iron parameters. The patients' ﬁbroblasts showed altered oxidative status,
reduced antioxidant defence, and impaired cytosolic and mitochondrial aconitase activities compared to control
cells. Mitochondrial iron homeostasis and functionality analysis of patient ﬁbroblasts indicated increased labile
iron pool content and reactive oxygen species development, alteredmitochondrial shape, decreasedmembrane po-
tential and reduced ATP levels. Furthermore, analysis of induced neurons, performed at a single cell level, conﬁrmed
some of the results obtained inﬁbroblasts, indicating an altered oxidative status and signs ofmitochondrial dysfunc-
tion, possibly due to iron mishandling. Thus, for the ﬁrst time, altered biological processes have been identiﬁed
in vitro in live diseased neurons. Moreover, the obtained induced neurons can be considered a suitable human neu-
ronal model for the identiﬁcation of candidate therapeutic compounds for this disease.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Neurodegeneration with brain iron accumulation (NBIA) is a hetero-
geneous group of genetic disorders characterised by radiological evidence
of focal accumulation of iron in the brain, usually in the basal ganglia and
extrapyramidal dysfunction (Schneider et al., 2013; Levi and Finazzi,
2014). These disorders are characterised by early or late onset, with the
main symptoms associated with problems in movement, spasticity and, deferoxamine; DHR-123,
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. This is an open access article undercognitive impairment. Approximately 50% of cases of NBIA can be ex-
plained by mutations in the PANK2 gene that cause an autosomal–reces-
sive form of the disease, termed pantothenate kinase-associated
neurodegeneration (PKAN or NBIA type I; OMIM 234200) (Hayﬂick,
2014). Magnetic resonance imaging (MRI) is particularly useful for
distinguishing the cases of PKAN from other NBIA forms. In the majority
of PKAN patients, the T2-weighted images show a hyperintense lesion
of the globus pallidus, surrounded by a hypointense area (Angelini et al.,
1992). This combination of hyper- and hypointense areas in the globus
pallidus gives rise to a pattern deﬁned as the “eye of the tiger”, which is
almost pathognomonic of the disease. The brain regions inwhich iron ac-
cumulates at pathological levels are the globus pallidus and substantia
nigra, where iron-positive spheroidal bodies are visible, usually in the vi-
cinity of swollen axons. Other neuropathological signs include demyelin-
ation, neuronal loss and gliosis (Kruer et al., 2011).
PANK2 codes for the pantothenate kinase-2 (PANK2), amitochondrial
enzyme that catalyses theﬁrst limiting step of the de novo biosynthesis of
coenzymeA(CoA). CoA is a key factor in several cellular processes, includ-
ing mitochondrial energy metabolism, anabolism and catabolism of fatty
acids, as well as protein biosynthesis (Leonardi et al., 2005). In humans, 4the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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localisation. Mutations in PANK2, which is located on chromosome 20,
are spread over all 7 exons and include missense, nonsense, frameshift
and splicing sitemutations (Hartig et al., 2006).Mutations in PANK2 result
in enzyme deﬁciency, leading to insufﬁciency of the ﬁnal product and ac-
cumulation of upstream substrates, such as N-pantotenoil-cysteine and
pantetheine, which are potentially toxic (Leoni et al., 2012). In particular,
cysteine is a potent iron chelator, and it has been proposed that high local
levels of cysteine are the basis of the subsequent accumulation of iron,
resulting in increased oxidative stress (Perry et al., 1985). The other hy-
pothesis to explain the observed iron accumulation suggests that alter-
ations in phospholipid metabolism due to CoA-deﬁciency may injure
the membranes, with consequent oxidative stress that leads to iron dys-
homeostasis (Leonardi et al., 2007). Different animal disease-models
have been developed using Drosophila melanogaster andMus musculus.
Drosophila PKAN models partially recapitulate the human phenotype,
showing locomotor dysfunction and neurodegeneration (Rana et al.,
2010). In addition, a Pank2 KO mouse model does not fully recapitulate
the human phenotype (Kuo et al., 2005), unless particular dietary condi-
tions are used (Brunetti et al., 2014). The double knock-out of more than
one Pank in mice produces a very drastic phenotype resembling a meta-
bolic syndrome (Garcia et al., 2012). However, these models do not
show iron accumulation in the brain and are not useful for studying the
pathogenetic mechanism leading to iron imbalance, which is hallmark
sign in the brains of patients. Two in vitro studies on cellular models
have attempted to explain the relationship between PANK2 deﬁciency
and iron deregulation. In HeLa, HepG2 and SH-SY5Y cells, the speciﬁc
siRNA silencing of PANK2 affects cell proliferation, induces cellular iron
deﬁciency and increases the expression of the iron exporter ferroportin
(Poli et al., 2010). PKAN ﬁbroblasts, maintained in chronic iron supple-
mentation, showed disturbed iron sensor protein iron regulatory protein
1 (IRP1) activity, resulting in deregulation of ferritin and transferrin re-
ceptor1 (TfR1), as well as a larger intracellular bioactive labile iron pool
(LIP). This effect results in higher reactive oxygen species (ROS) develop-
ment and leads to increased cellular oxidative status (Campanella et al.,
2012).
Mitochondria are the main sites of iron utilisation in the cell (Levi
and Rovida, 2009). This organelle employs the metal to sustain the bio-
synthesis of the iron sulphur cluster (ISC) and heme cofactors,which are
prosthetic groups ofwidespread proteins involved in key biological pro-
cesses, such as electron transfer, DNA synthesis and repair, metabolic
and regulatory processes (Stehling et al., 2014). Thus, mitochondria
play a central role in cell life, not only for energy supply but also for cel-
lular iron handling. This important role is highlighted by the fact that
defects in mitochondrial iron homeostasis lead to pathological pheno-
types and cell death (Levi and Rovida, 2009). Here, we evaluated mito-
chondrial functionality in terms of iron handling and energetic proﬁle to
investigatewhether the iron-dependent oxidative status alteration, pre-
viously revealed in PKAN patients' ﬁbroblasts (Campanella et al., 2012),
also affects themitochondrial compartment. Furthermore, by taking ad-
vantage of the recently developed technology (Amamoto and Arlotta,
2014; Caiazzo et al., 2011) that allows neurons to be directly
transdifferentiated from ﬁbroblasts, we generated induced neurons
(iNs) from PKAN patients to establish a suitable disease model in
which to study the consequences of PANK2 dysfunction.
Material and methods
Cell culture
We used primary skin ﬁbroblasts from three unaffected subjects
(controls 1, 2 and 3, two neonatals and one adult) purchased from
ATCC and from three PKAN patients selected from theMovement Disor-
ders Bio-Bank available at theNeurogeneticsUnit of theNeurological In-
stitute ‘Carlo Besta’ (INCB), Milan, Italy. Two PKAN patients (marked
F419fsX472(a) and F419fsX472(b), biopsy was made at the age of twoand four years old) (Campanella et al., 2012)were brothers who are ho-
mozygous for the same frame shift mutation that results in a truncated
PANK2 protein (F419fsX472). The third, Y190X (Hartig et al., 2006),was
homozygous for amutation that produced a truncated amino acid chain.
The ﬁbroblasts were grown in DMEM (Lonza) supplemented with 10%
FBS (Lonza), 100 mg/ml streptomycin, 100 U/ml penicillin and 4 mM
L-glutamine (Sigma).Generation of iNs from human ﬁbroblasts by direct reprogramming
Human ﬁbroblasts from patients and controls were grown in medi-
um for ﬁbroblasts (DMEM, FBS, nonessential amino acids, sodium pyru-
vate, and penicillin/streptomycin) plated onto Matrigel-coated 24-well
plates (5 × 104 cells/well). For the immune-histochemical analysis,
some of these cells were plated onto Matrigel-coated glass coverslips.
On the second day, the ﬁbroblasts were infected by lentivirus in which
cDNAs for transcription factors (Mash1, Nurr1, and Lmx1a) had been
cloned (Caiazzo et al., 2011) under the control of a tetracycline-
responsive promoter. Sixteen to twenty hours after infection, the cells
were switched into fresh ﬁbroblast medium containing doxycycline
(2mg/ml), and after a further 48 h, themediumwas replacedwith neu-
ronal inducing medium (DMEM F12, 25 μg/ml insulin, 50 μg/ml trans-
ferrin, 30 nM sodium selenite, 20 nM progesterone, and 100 nM
putrescine and penicillin/streptomycin) containing doxycycline (all
from Sigma). The medium was changed every 2–3 days for a further
20 days.Immunoblotting
Soluble cellular extracts for immunoblotting were obtained by lys-
ing cells in 20mMTris–HCl, pH7.4, 1% TritonX-100, and protease inhib-
itor cocktail (Roche) followed by centrifugation at 16,000 g for 10 min.
Fifteen micrograms of total proteins was separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and immu-
noblotting was performed using speciﬁc antibodies: anti-citosolic
aconitase (cAco) (Campanella et al., 2012) was used at a dilution of
1:500; anti-mitochondrial aconitase (mAco) (Antibody Verify) was
used at a ﬁnal concentration of 1 μg/ml; the anti-β-actin antibody
(Sigma) was used at a dilution of 1:6000; the mouse monoclonal anti-
PANK2 (Origene) antibody was used at a dilution of 1:2000; and the
mouse monoclonal anti-SDH (70 kDa subunit) (MitoScience) was
used at a ﬁnal concentration of 0.1 μg/ml, followed by peroxidase-
labelled secondary antibodies (Sigma-Aldrich). Band intensity was re-
vealed by the ECL-chemiluminescence kit (GE Healthcare). The total
protein contents were measured using the BCA protein assay (Thermo
Fisher Scientiﬁc) calibrated with bovine serum albumin.Determination of aconitase activity
Aconitase activity was in-gel assayed as described in Tong and
Rouault (2006). The patient and control ﬁbroblasts were grown in
DMEM, harvested, washed in PBS and lysed in 20 mM Tris–HCl buffer,
pH 7.4, 1% Triton X-100, protease inhibitor cocktail, 2 mM citrate,
0.6 mM MnCl2, and 40 mM KCl. Soluble extracts (40 μg) in 25 mM
Tris–HCl, pH 8.0, 10% glycerol, bromophenol blue, were loaded on
PAGE gels containing 8% acrylamide, 132mMTris base, 132mMborate,
and 3.6mMcitrate in the separating gel; and 4% acrylamide, 67mMTris
base, 67mMborate, 3.6mMcitrate in the stacking gel. The runwas per-
formed at 180 V for 2.5 h at 4 °C. Aconitase activity was determined in
the dark at 37 °C by incubating the gel in 100 mM Tris–HCl, pH 8.0,
1 mM NADP, 2.5 mM cis-aconitic acid, 5 mM MgCl2, 1.2 mM MTT,
0.3 mM phenazine methosulfate, and 5 U/ml isocitrate dehydrogenase.
The quantiﬁcation of the signal was performed using the NIH image
software ImageJ.
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Heme content was measured in ﬁbroblasts from patients and con-
trols as previously described (Santambrogio et al., 2011). Brieﬂy, the
cells were washed with phosphate-buffered saline and dissolved in
0.25 ml of 98% formic acid and incubated for 15 min. The heme content
was evaluated by analysing the clear supernatant at 400nm,with an ex-
tinction coefﬁcient of 1.56 × 105 ×M−1 × cm−1. The datawere normal-
ised to protein content as determined by the BioRad Protein Assay
(BioRad).
Oxidised protein detection
Oxidised proteins were detected using the OxyBlot Protein Oxida-
tionDetection Kit (Millipore) following themanufacturer's instructions.
Brieﬂy, 10 μg of the soluble cellular extracts was derivatised to 2,4
dinitrophenylhydrazone, and 5 μg was loaded on a 12% SDS-PAGE gel,
blotted and incubated with an anti-DPN antibody. The bound activity
was revealed by a ECL-chemiluminescence kit (GE Healthcare).
Glutathione measurement
Fibroblasts, treated or not with 1 mM TCEP (tris[2-
carboxyethyl]phosphine) for 30 min at 37 °C, were incubated with
20 μM ThiolTracker Violet (Invitrogen) for 30 min at 37 °C, washed
with PBS and ﬁxed in 4% paraformaldehyde in PBS for 20 min at
room temperature. The images were acquired by Zeiss Axiovert 135
TV ﬂuorescence microscope, and the ThiolTracker Violet signal was
quantiﬁed by ImageJ software. iNs were incubated with 20 μM
ThiolTracker Violet (Invitrogen) for 30 min at 37 °C, washed with
PBS and ﬁxed in 4% paraformaldehyde in PBS for 20min at room tem-
perature. The cells were then permeabilised for 3min in PBS contain-
ing 0.1% Triton X100 and 10% normal goat serum. Next, the cells were
incubated with Alexa Fluor 647 mouse anti-human CD56 (N-CAM,
BD Biosciences, diluted 1:40) for 1 h at 37 °C, and with 2 μg/ml
Hoechst for 2 min. After washing, the cells were analysed by IN Cell
Analyzer 1000 system (GE Healthcare). The ThiolTracker Violet ﬂuo-
rescence in N-CAM-positive cells was collected to compare relative
glutathione contents.
Determination of LIP
LIP was measured using the iron-sensitive ﬂuorescent probe RPA
(rhodamine B-[(1,10-phenanthrolin-5-yl)-aminocarbonyl]benzyl ester)
(Squarix Biotechnology). Control of ﬂuorescence probe incorporation
was performed with RPAC (rhodamine B-[(phenanthren-9-yl)-
aminocarbonyl]-benzylester), an analogue of RPA but without iron bind-
ing capacity and subsequent quenching. Brieﬂy,ﬁbroblastswere plated in
96-well plates and incubated with or without 100 μM FAC and 200 μM
ascorbic acid (Sigma) for 18 h. The cells were incubated in HBSS supple-
mented with 10 mM glucose and 2 μM RPA or RPAC for 15 min at 37 °C.
After two washes with HBSS, the cells were maintained in HBSS supple-
mented with 10 mM glucose. Basal ﬂuorescence was measured using a
Victor3Multilabel Counter (Wallac, Perkin Elmer) at 530 nm (excitation)
and 590 nm (emission). The quenching of RPA by ironwas revealed after
the addition of the speciﬁc iron chelator PIH (ﬁnal concentration: 2 mM)
for 30 min. The results were normalised for protein content.
Determination of ROS
Fibroblasts were incubated with 30 μM dihydrorhodamine-123
(DHR-123, Molecular Probes) for 15 min at 37 °C and then washed
with PBS and maintained in HBSS supplemented with 10 mM glucose.
The ﬂuorescence was determined using the Victor3 Multilabel Counter
(PerkinElmer) at 485 and 535 nm for excitation and emission,respectively. The cells were incubated in HBSS for 30 min at 37 °C
with 0.3 M H2O2, and ﬂuorescence was determined as above.
iNs generated from ﬁbroblasts were incubated with Alexa Fluor 647
mouse anti-human CD 56 (anti-N-CAM; BD Biosciences) for 1 h, with
20 μM of 2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCFDA; Molec-
ular Probes) for 15 min and with 2 μg/ml of Hoechst 33342 for 2 min.
All of these incubationswere performed at 37 °C. The cells werewashed
and analysed using an IN-Cell Analyzer 1000 system (GE Healthcare).
The ﬂuorescence of DCF from N-CAM-positive cells was collected to
compare the relative ROS contents.
Determination of mitochondrial membrane potential
Fibroblasts were incubated with 4 μg/ml of oligomycin (Sigma) for
1 h at 37 °C and with 2 μg/ml of Hoechst 33342 for 2 min. Then,
20 nM of tetramethylrhodamine methyl ester (TMRM; Molecular
Probes) was added, and its incorporation was followed by analysis
with the IN-Cell Analyzer 1000 system for 2 h. Next, 4 μg/ml of FCCP
(Sigma) was added to depolarise the mitochondrial membrane, and
TMRM signal followed for other 10 min.
iNs generated from ﬁbroblasts were incubated with Alexa Fluor 488
mouse anti-human CD 56 (anti-N-CAM; BD Biosciences) for 1 h, with
20 μM of TMRM (Molecular Probes) for 15 min, and with 2 μg/ml of
Hoechst 33342 for 2 min. All of these incubations were performed at
37 °C. The cells were washed and analysed by the IN-Cell Analyzer
1000 system (GE Healthcare). The ﬂuorescence of TMRM from N-
CAM-positive cells was collected to compare the relative mitochondrial
membrane potential.
Analysis of mitochondrial network and Shape Factor
The cells were plated on 35-mm glass-bottom dishes in complete
DMEM. After 24 h, Mitotracker Red (Invitrogen) was added at a ﬁnal
concentration of 10 nM for 30min at 37 °C. The cells were then washed
three times with PBS, and a medium with 25 mM HEPES and without
Phenol Red was added. Fluorescence was visualised on an Axiovert
200 epiﬂuorescence inverted microscope (Zeiss, Germany) equipped
with a 40× ﬂuorite objective using a CARV II Confocal Imager (BD Bio-
sciences). The images were acquired using a CCD camera (Roper Scien-
tiﬁc, USA). All of the imaging data were collected and analysed using
MetaMorph acquisition/analysis software (Universal Imaging Corp.,
Downingtown, PA, USA).
The amount of mitochondrial fragmentation was evaluated using
the Shape Factor function of the MetaMorph software. Shape Factor
evaluates the circular shape of an object and attributes a score near 0
in the case of a ﬂattened object and a score near 1 for a perfect circle.
We deﬁned three shape factor groups to classify the different morphol-
ogies of the mitochondrial networks: Group I: shape factor 0–0.3
consisted of cells with a ﬁlamentous mitochondrial network; Group II:
shape factor 0.3–0.6 consisted of cells with ﬁlamentous network but
with the presence of round-shaped mitochondria; and Group III:
shape factor 0.6–1 consisted of cells with high fragmentation with
only round-shaped mitochondria. For each cell type, a total of 100 im-
ages, collected in four different experiments, were used to calculate
the percentage of the different shape factors.
ATP evaluation
Fibroblasts were plated at 8000 cells/well in 96-well plates. The
next day, total cellular ATP was measured using the ATPlite kit
(PerkinElmer Life Sciences) according to the manufacturer's proce-
dure. This method is based on the mono-oxygenation of luciferin,
which is catalysed by luciferase in the presence of Mg2+, ATP, and
oxygen, resulting in a luminescent signal that is proportional to the
ATP concentration. The plate was read on a Victor plate reader
(Perkin Elmer) in luminescence mode. The cell numbers were
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normalised for cell number.Statistical analyses
The data, except where otherwise indicated, are reported as the
mean+/− SD values or as representative of at least three independent
experiments with similar results. Statistically signiﬁcant differences be-
tween controls and patients were determined in all the experiments by
one-way ANOVA analyses with Bonferroni's post-test and by Student's
t-test; *, ** and *** indicated p b 0.05, p b 0.01 and p b 0.001, respectively.
A p value b0.05 was considered statistically signiﬁcant. Both analyses
gave similar signiﬁcance except where speciﬁed.Results
PKAN ﬁbroblasts show altered iron dependent oxidative status
We analysed ﬁbroblasts from three PKAN patients and healthy
subjects. One PKAN patient carried a homozygous c.569insA mutation
that resulted in a premature stop codon at amino acid position 190
(p. Y190X) (Hartig et al., 2006); the other two patients are brothers
and carried a homozygous c.1259delG mutation, producing a frame
shift mutation resulting in the substitution of 53 amino acids and the
creation of a stop codon (F419fsX472) (Campanella et al., 2012; Zorzi
et al., 2011). As shown bywestern-blot analysis in Fig. 1A, PANK2 is vir-
tually absent in all three patients, whilst a normal level of the protein is
present in the controls. We then determined cellular oxidative status
and its relationship with iron content in these cells by treating control
and PKAN ﬁbroblasts with the iron-chelator deferoxamine (DFO) for
18 h. The content of carbonylated proteins in the DFO-treated and un-
treated cellular extractswas then evaluated byOxyblot (Fig. 1B). The re-
sults conﬁrmed that untreated PKAN ﬁbroblasts showed increased
carbonylated protein levels compared to control cells (Fig. 1B, DFO−).
Interestingly, whilst DFO treatment ameliorated the level of
carbonylated proteins in PKAN ﬁbroblasts, it was completely ineffective
in control ﬁbroblasts (Fig. 1B, DFO+). Moreover, by monitoring
ThiolTracker Violet intensity, we observed a signiﬁcant reduction in
levels of both total and reduced glutathione in PKAN ﬁbroblasts com-
pared to controls (Fig. 1C).Fig. 1. PKAN ﬁbroblasts show altered oxidative status. (A) The determination of the PANK2 p
(47 kDa) and to SDH70 used as loading control. The other lower band, present in patients an
not with 100 μM deferoxamine (DFO) for 18 h, and the levels of carbonylated proteins in solu
experiments is shown. (C) Measurements of total and reduced glutathione content in ﬁbroblas
quired by ﬂuorescence microscopy, and the quantiﬁed signal, relative to controls, was plott
**p b 0.01, ***p b 0.001.PKAN ﬁbroblasts show mitochondrial iron homeostasis dysfunction
Toverifywhether the defect in PANK2 activity affectedmitochondri-
al iron homeostasis, we tested for the presence of potentially toxic free
iron (LIP) in themitochondrial compartment using the iron sensingmi-
tochondrial target-speciﬁc ﬂuorescent probe (rhodamine B-[(1,10-
phenanthrolin-5-yl)-aminocarbonyl]benzyl ester, RPA). This probe has
been largely used with success in previous works to speciﬁcally mea-
sure the mitochondrial LIP (Cabantchik, 2014; Ma et al., 2015; Rauen
et al., 2007). Rhodamine B-[(phenanthren-9-yl)-aminocarbonyl]-
benzylester (RPAC), an analog of RPA but without iron binding capacity
and subsequent quenching, was used to monitor the incorporation of
the probe driven by mitochondrial-membrane-potential in the control
and patients' cells. The cells were incubated with or without 100 mM
ferric ammonium citrate (FAC) for 18 h. The RPAC ﬂuorescence was
measured and the results indicated that the amount of incorporated
probe was similar in control and patients' cells in all the conditions
(not shown). Then, RPA ﬂuorescence was measured before and after
the addition of the iron chelator PIH (pyridoxal isonicotinoyl
hydrazone) (Rauen et al., 2007). The result indicated that the size of
the mitochondrial LIP was statistically higher in PKAN ﬁbroblasts than
in control cells in both basal growth conditions (Fig. 2A) and with iron
supplementation (not shown). As labile iron can promote ROS forma-
tion, we measured their generation using the ROS sensitive mitochon-
drial probe dihydrorhodamine 123 (DHR-123) in basal growth
condition and after iron supplementation (Campanella et al., 2009).
The ﬂuorescence intensity was signiﬁcantly higher in PKAN ﬁbroblasts
than in controls under basal growth conditions (Fig. 2B) and after iron
addition (not shown). In PKAN cells only, this difference further in-
creased after incubation with 0.3 mMH2O2 both in basal growth condi-
tion (Fig. 2C) and after iron supplementation (not shown). To test the
efﬁciency of ISC biosynthesis, we evaluated the in-gel enzymatic activi-
ty of cAco and mAco, two ISC-containing proteins, after separation on
non-denaturing PAGE (Fig. 2D, upper panel), a higher sensible method
with respect to the one previously used (Campanella et al., 2012). Den-
sitometric analysis of the bands showed a reduced enzymatic activity of
both aconitase forms (Fig. 2D, lower panels). However, the amount of
aconitase proteins as evaluated by western blotting with speciﬁc anti-
bodies was similar between PKAN and control ﬁbroblasts (not
shown). Furthermore, we evaluated heme biosynthesis that, other
than depending on the ISC-containing ferrochelatase, represents the
other major iron-containing product in mitochondria. We measuredrotein content in ﬁbroblast soluble extracts. The arrows point to PANK2 mature peptide
d controls, is a non-speciﬁc reaction of the antibody. (B) The ﬁbroblasts were treated or
ble cell extracts were then analysed by Oxyblot. One representative of three independent
ts evaluated using the speciﬁc ﬂuorescent probe ThiolTracker Violet. The images were ac-
ed as the mean and standard deviation of three independent experiments in triplicate.
Fig. 2. PKANﬁbroblasts show alteredmitochondrial iron handling. (A) The evaluation of themitochondrial LIP in untreatedﬁbroblasts by the speciﬁc probe RPA. Themean and SDof three
independent experimentsmade in quadruplicate, and the bars indicate statistically signiﬁcant differences, * p b 0.05. (B and C) The cells were treated or not with 0.3mMH2O2 for 30min,
and the mitochondrial ROS generation was evaluated on untreated B or treated C ﬁbroblasts using the ﬂuorescent probe DHR-123. The mean and SD of three independent experiments
made in quadruplicate, *p b 0.05, **p b 0.01. (D) The enzymatic activity of aconitase was evaluated on soluble cell homogenates that were separated on non-denaturing PAGE gels. The
arrows indicate the position ofmitochondrial aconitase (mAco), of cytosolic aconitase (cAco) and of the protein band stainedwith Coomassie blue used for loading control. The histograms
show the densitometry of aconitase bands relative to controls, with the mean and SD of three independent experiments, *p b 0.05, **p b 0.01, ***p b 0.001. (E) The evaluation of heme
content in untreated ﬁbroblasts by absorbance at 400 nm of the soluble cell lysates. The mean and SD of six independent experiments, *p b 0.05, ***p b 0.001.
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tracts from cells lysed in formic acid at 400 nm. We observed a signiﬁ-
cant difference in heme content, corresponding to a 25% reduction in
PKAN compared to the control ﬁbroblasts (Fig. 2E).
PKAN ﬁbroblasts show energetic mitochondrial dysfunction
We further investigated the ability of mitochondria to maintain the
cellular energy requirement. The mitochondrial membrane potential
was evaluated with the mitochondria-speciﬁc ﬂuorescent probe
tetramethylrhodamine methyl ester (TMRM) on ﬁbroblasts in thepresence of the ATPase inhibitor oligomycin. The kinetics of TMRM incor-
porationwas followed for 2 h bymonitoring theﬂuorescence of the probe
using the IN-Cell Analyzer 1000 system. Starting from 30 min, the mean
kinetics of the controls was statistically higher than for PKAN patient ﬁ-
broblasts (Fig. 3A, *p b 0.05). These data indicated that the PKAN ﬁbro-
blasts incorporated less probe compared to control cells, suggesting
lowermembrane hyperpolarisation.We investigatedmitochondrialmor-
phology after loading cellswithMitotracker Red and examinationbyﬂuo-
rescencemicroscopy. Theﬁbroblastswere scored into different categories
on the basis of mitochondrial morphology. Representative images of
these classes of mitochondrial morphology are shown in Fig. 3B. A total
Fig. 3. PKAN ﬁbroblasts show alteredmitochondrial functionality. (A) The ﬁbroblasts were incubatedwith 4 μg/ml of oligomycin for 1 h, and the mitochondrial-speciﬁc ﬂuorescent probe
TMRMwas then added. Its incorporationwas followed using the IN-Cell Analyzer 1000 system for 2 h. Plots, normalised on starting points, show the kinetics of TMRM incorporation,with
themean and SEM of three independent experiments, * p b 0.05 from 30minwith the exception of patient Y190X that resulted signiﬁcant only from 60min by one-way ANOVA analyses
with Bonferroni's post-test. The arrow indicates the time of FCCP addition. (B) Fibroblasts were incubated with MitoTracker Red ﬂuorescent probe. The evaluation of the mitochondrial
shape factor was performed on images obtained by ﬂuorescence microscopy. The histogram shows the percentage of cells with the indicated shape factor, with the mean and SD of
four independent experiments, **p b 0.01, ***p b 0.001. (C) Evaluation of ATP content in ﬁbroblasts. Total ATP levels were evaluated by the ATPlite kit. The data are presented as the
mean of two controls (reported as a single bar) and three patients, reported separately, with the mean and SD of three independent experiments. *p b 0.05, ***p b 0.001.
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The amount of mitochondrial fragmentation was evaluated using the
Shape Factor function of MetaMorph software. This function evaluates
the circular shape of an object and attributes a score near 0 in the case
of a ﬂattened object and a score near 1 for a perfect circle. The Shape Fac-
tor average of PKAN patients' ﬁbroblasts was closer to 1 than in the con-
trol subjects. The mitochondrial network of PKAN patients with loss-of-
functionmutationswasmore fragmented than controls, indicating an im-
paired bioenergetic proﬁle. The difference between these two samples
was statistically signiﬁcant (Fig. 3B upper panel; *p b 0.05; **p b 0.01).
In line with this observation, we observed a reduction in ATP levels in
PKAN ﬁbroblasts compared to control cells (Fig. 3C; *p b 0.05; **p b 0.01).
Generation and characterisation of induced neurons from PKAN ﬁbroblasts
Human neurons were generated from patient and control ﬁbroblasts
by direct neuronal reprogramming (Caiazzo et al., 2011; Cozzi et al.,
2013). Lentiviruses expressing the transcription factor combination
Ascl1, Nurr1 and Lmx1a were used to transduce ﬁbroblasts to generate
iNs, whichwere thenmaintained in a neurobasal medium supplemented
with a cocktail of growth factors and inducing molecules (see the
Material andmethods section). iNs were identiﬁed in the reprogrammed
cell culture by immunostainingwith the speciﬁc neuronalmarker class III
β-tubulin (TuJ1), N-CAM andMAP2, as well as the dopaminergic-speciﬁc
enzyme tyrosine hydroxylase (TH) (Fig. 4A and data not shown). At least
50% of the TuJ1-positive cells were also positive for TH. We used TuJ1-
positive cells to evaluate neuronal reprogramming efﬁciency, which
was approximately 5% and comparable between PKAN and control cells
(Fig. 4B). We then used iNs to evaluate several parameters, including
the oxidative status and mitochondrial functionality. Due to the lowefﬁciency of direct cellular reprogramming, we developed a method for
in vivo analysis at single cell level by selecting the live neurons using
the speciﬁc neuronal membrane marker N-CAM.
PKAN induced neurons show altered oxidative status
First, we analysed the amount of ROS speciﬁcally present in iNs
grown in basal conditions. The cellswere incubatedwith theﬂuorescent
ROS-sensitive dichloroﬂuorescein (DCF), and the images were acquired
by the IN-Cell Analyzer 1000 system. The identity of iNs was veriﬁed by
the expression of the neuronal speciﬁc marker N-CAM, and only the N-
CAM-positive cells were utilised to calculate the ﬂuorescence of the DCF
(Fig. 4C). The quantiﬁcation of ﬂuorescent intensity speciﬁc to iNs indi-
cated that PKAN iNs contained higher ROS levels than control iNs
(Fig. 4D). Moreover, an analysis of ThiolTracker Violet treated cells re-
vealed that PKAN iNs contained signiﬁcant lower reduced glutathione
levels compared to control iNs (Fig. 4E).
PKAN induced neurons show alterations in mitochondrial membrane
potential
A similar approachwas used to evaluatemitochondrial functionality
in neuronal cells. We measured mitochondrial membrane potential by
quantifying the TMRM signal 15 min after treatment with the probe;
the images were collected as above. As previously described, only N-
CAM-positive cells were utilised to calculate the TMRM ﬂuorescence
(Fig. 4F). The quantiﬁcation of TMRM intensity showed that PKAN iNs
had signiﬁcantly lower membrane potentials compared to control iNs
(Fig. 4G).
Fig. 4. Characterisation of induced neurons obtained from PKAN ﬁbroblasts by direct reprogramming. (A) The induced neuronswere stained for neuronal class III beta tubulin (α-Tuj1, top
panels in red) and tyrosine hydroxylase (α-TH,middle panels in green). Hoechst was used to stain cell nuclei (in blue), and the lower panels show themerged images, scale bar=100 μm.
Tuj1, a neuronal marker, was used to calculate the reprogramming efﬁciency, and the results are plotted in panel B. (C) Live cells stainedwith the ROS-sensing ﬂuorescent probe DCF (top
panels in green) andwith the neuron-speciﬁc anti-N-CAMantibody (middle panels in red); merged images are shown in the lower panels, with the nuclei stainedwith Hoechst. Theﬂuo-
rescencewas analysedusing the INCell Analyser 1000 System, scale bar=100 μm. (D) TheDCFﬂuorescence signal fromN-CAM-positive cells (frompanel C)were quantiﬁed, and thedata
are shown in the plots as themean and SDof three independent experiments (at least 50 neurons per type), *p b 0.05. (E) The ThiolTracker Violetﬂuorescence signal fromN-CAM-positive
cells was quantiﬁed (experiments were performed as in panel C, with ThiolTracker in place of DCF), and the data are shown in the plots as the mean and SD of three independent exper-
iments (at least 50 neurons per type), *p b 0.05, **p b 0.01. (F) Live cells were stainedwith themitochondrial membrane potential sensible ﬂuorescent probe TMRM (middle panels in red)
andwith theneuron-speciﬁcα-N-CAMantibody (toppanels in green). Themerged images are shown in the lower panels,with nuclei stainedwithHoechst. Theﬂuorescencewas analysed
using an IN-cell analyser, scale bar=100 μm. (G) The TMRM ﬂuorescence signal fromN-CAM-positive cells (from panel F)was quantiﬁed, and the data are shown in the plots as themean
and SD of three independent experiments (at least 50 neurons per type), **p b 0.01, ***p b 0.001.
150 P. Santambrogio et al. / Neurobiology of Disease 81 (2015) 144–153
151P. Santambrogio et al. / Neurobiology of Disease 81 (2015) 144–153Discussion
PKAN is a severe and disabling neurodegenerative disorder, the
pathogenic mechanisms of which are largely unknown (Zhou et al.,
2001). The low amount of CoA due to the PANK2 enzymatic defect has
a devastating impact on many biological processes. CoA is utilised as a
cofactor in approximately 4% of all known enzymes; thus, its imbalance
inhibits awide range of enzymatic pathways (Leonardi et al., 2005). This
effectwas highlighted by the studies of PKANdiseasemodels inﬂies and
mice. These analyses revealed different types of CoA-deﬁciency related
phenotype, such as the following: sterility (Afshar et al., 2001; Kuo
et al., 2005); abnormal locomotor function, neurodegeneration, and re-
duced life span (Bosveld et al., 2008); mitochondrial impairment
(Brunetti et al., 2012; Rana et al., 2010); altered cytoskeleton function
(Siudeja et al., 2012); protein acetylation (Siudeja et al., 2011);
disrupted circadian locomotor patterns and a unique transcriptional sig-
nature (Pandey et al., 2013). However, all of these investigations have
not clariﬁed the mechanism of one of the major features of the human
disease, brain iron accumulation, which has not been reported neither
in ﬂies nor in mice (Brunetti et al., 2012; Rana et al., 2010).
To approach this question, we previously examined iron metabolism
in PKAN ﬁbroblasts, demonstrating an abnormal behaviour of PANK2 de-
ﬁcient cells in response to treatment with iron and the consequent alter-
ation of oxidative status (Campanella et al., 2012). In the previous study,
we concentrated our attention on cytosolic iron handling. As mitochon-
drial iron homeostasis and cytosolic iron homeostasis are strictly interre-
lated, we hypothesised that iron mishandling could also occur in the
mitochondria, thereby affecting organelle functionality. For this reason,
we extended our analysis to mitochondria to determine whether and
howmitochondrial iron alteration could impact on the cell's bioenergetic
proﬁle. Interestingly, we detected a larger mitochondrial LIP also under
basal conditions, whereas the increase in the size of the cytosolic LIP
was appreciable only after chronic iron supplementation (Campanella
et al., 2012). Nevertheless, the availability of high levels of mitochondrial
iron did not appear to be properly utilised in ISC and heme biosynthesis,
thus they resulted defective in PKANﬁbroblasts. The reasonswhy this oc-
curs and how the PANK2 deﬁciency is involved are still obscure. Very re-
cent data, obtained on isolated mammalian mitochondria, demonstrated
that ISC biosynthesis requires, other than iron and sulphur, also GTP,
NADH and ATP (Pandey et al., 2015). A very reliable hypothesis could
be that the impairment of the Krebs cycle due to CoA deﬁciencymight re-
sult in lower production of GTP and NADH, with the consequent partial
iron utilisation in ISC biosynthesis.
Moreover, LIP and ROS are tightly controlled in cell and large varia-
tions are not expected. In fact, the detected increased size of the LIP re-
sulted in a slight increase inmitochondrial ROS production, which plays
a central role in the regulation of ISC enzyme activity and, in particular,
in Acos enzyme functions. Both the cAco and mAco contain [4Fe–4S]
clusters that are responsible for their catalytic activity, which is regulat-
ed by reversible oxidation (Bulteau et al., 2003). The main role of mAco
is to control cellular ATP production via the regulation of intermediate
ﬂux in the Krebs cycle. cAco has two different functions: in the ISC-
containing form, it operates as an enzyme, whereas in the oxidised
form, it is involved in the control of iron–protein translation as IRP1
(Lushchak et al., 2014). Thus, the reduction of their activities, caused
by their higher oxidation produced by ROS or by diminished production
of ISC, has an effect both on ATP production and iron homeostasis,
which we demonstrated to be altered in PKAN ﬁbroblasts.
In addition, other mitochondrial features appeared defective in pa-
tients' cells, such as the mitochondrial membrane potential and mito-
chondrial morphology, suggesting a global organelle impairment,
which can lead to energetic failure. Interestingly, a mitochondrial mor-
phology alteration was also recently reported in the muscles of a PKAN
patient with a deﬁned genetic mutation (Brunetti et al., 2014), indicat-
ing that variation of mitochondrial morphology can also be detected
in vivo in different patient cell types. An altered mitochondrialmembrane potential was also detected in neurons derived from a
Pank2 KO mouse model (Brunetti et al., 2012).
Obviously, we cannot exclude the possibility that the energetic im-
pairment detected in PKAN ﬁbroblasts could also derive frommembrane
alterations due to CoA deﬁciency-induced defects in phospholipid syn-
thesis; more detailed studies are needed to clarify this point. In fact, the
partial mitochondrial swelling and depolarisation detected in PKAN ﬁ-
broblasts suggestmitochondrialmembrane damage. However, as report-
ed by previous studies on isolated rat liver mitochondria, iron may
catalyse the peroxidation of lipids in themitochondrial inner membrane,
which can result in a limited depolarisation (Gall et al., 2012). Mitochon-
drial membrane depolarisation is a strong stimulus for opening themito-
chondrial permeability transition pore (Bernardi et al., 1992; Gogvadze
et al., 2003), which is considered one of the causative events of neuronal
injury (Crompton, 2004). The opening of the pore may facilitate mito-
chondrial iron import from the cytosolic compartment, further increasing
the size of themtLIP, not utilised by the intra-mitochondrial biosynthetic
pathways, thus exacerbating the injury.
Extensive studies on Saccharomyces cerevisiaedemonstrated that the
cells respond to reduced ISC synthesis with increased cellular iron up-
take and intracellular iron re-distribution, resulting in mitochondrial
iron accumulation until themetal precipitates as an amorphousmineral
(Lill andMuhlenhoff, 2008). These pathologic events have also been de-
scribed to occur in human disorders, such as Friedreich's ataxia
(Koeppen et al., 2007; Vaubel and Isaya, 2013) and Parkinson disease
(Horowitz and Greenamyre, 2010a; Mastroberardino et al., 2009) as
well as during the physiological ageing process (Isaya, 2014). In fact,
in recent times, there has been growing evidence of the role of mito-
chondrial iron dysfunction in the pathogenesis of commonneurodegen-
erative diseases (Horowitz and Greenamyre, 2010b). Overall, the data
indicate that defects in mitochondrial ISC biogenesis seem to represent
a common primary mechanism, which triggers abnormal intracellular
iron distribution. This effect results in cytosolic iron starvation and mi-
tochondrial iron accumulation, oxidative phosphorylation deﬁcits and
oxidative stress (Isaya, 2014; Nunez et al., 2012).
To clarify whether this abnormal iron distribution has a primary or a
secondary etiopathological role or is simply an epiphenomenon, more
work on different disease models is necessary. In any case, even if iron
dysregulation in PKAN may play a secondary role, its accumulation is
harmful and can aggravate the damage observed in the basal ganglia,
thus possibly justifying the iron chelation treatment proposed in pa-
tients (Zorzi et al., 2011). Certain brain regions, such as the globus
pallidus and the substantia nigra, have high iron contents, which are
necessary for the synthesis of neurotransmitters. These regions are par-
ticularly prone to the process of abnormal intracellular iron distribution,
which may also contribute to the age-dependent iron accumulation
(Isaya, 2014; Urrutia et al., 2013). We approached this question
employing direct neuronal cell reprogramming technology (Amamoto
and Arlotta, 2014; Caiazzo et al., 2011), which allowed us to obtain
human neurons starting from ﬁbroblasts. Although this technique has
an overall low efﬁciency in neuronal generation, we succeeded in
obtaining enough neurons from PKAN and healthy subject ﬁbroblasts
for an in depth analysis. Our data indicate that it is feasible to generate
human neuronal cells, even in cases of genetic alterations that lead to
mitochondrial impairment, as in the case of PKAN. In addition, as previ-
ously determined in ﬁbroblasts, our results conﬁrm, for the ﬁrst time in
PKAN induced neurons, the presence of an altered oxidative status in
basal conditions and the impairment of mitochondrial functions. iN
technology represents a very powerful system to investigate disease-
relevant pathogenetic mechanisms. However, this technology does not
currently allow the generation of striatal neurons, which represent the
most affected neuronal population in PKAN. Considering how fast direct
neuronal reprogramming technologies have been developing, we pre-
dict that an even more appropriate human neuronal model will be
soon available to further investigate PKAN pathogenetic mechanisms.
Nevertheless, our approach has enabled the identiﬁcation of altered
152 P. Santambrogio et al. / Neurobiology of Disease 81 (2015) 144–153biological processes that are relevant in diseased neurons; therefore, the
present results are more relevant than the analyses of other cell types.
Our results indicate that PANK-iNs might also represent a suitable sys-
tem for establishingmedium-scale drug screenings to identify new can-
didate therapeutic compounds for this disease.
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